Precision BioSciences logo

Precision BioSciencesNASDAQ: DTIL

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

28 March 2019

Next earnings report:

27 March 2025

Last dividends:

N/A

Next dividends:

N/A
$59.53 M
-89%vs. 3y high
37%vs. sector
129.33
-20%vs. 3y high
95%vs. sector
-84%vs. 3y high
40%vs. sector
-90%vs. 3y high
21%vs. sector

Price

after hours | Sat, 16 Nov 2024 00:06:10 GMT
$7.76+$0.11(+1.44%)

Dividend

No data over the past 3 years
$576.00 K$4.28 M
$576.00 K-$16.43 M

Analysts recommendations

Institutional Ownership

DTIL Latest News

Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis B
businesswire.com15 November 2024 Sentiment: POSITIVE

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, today will present preclinical data supporting the advancement of PBGENE-HBV into clinical development. The Company will also outline the design of its first-in-human study, ELIMINATE-B, in patients with chronic hepatitis B. Company management will present these upd.

Precision BioSciences (DTIL) Reports Q3 Loss, Misses Revenue Estimates
zacks.com04 November 2024 Sentiment: NEGATIVE

Precision BioSciences (DTIL) came out with a quarterly loss of $2.83 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to loss of $3 per share a year ago.

Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update
businesswire.com04 November 2024 Sentiment: POSITIVE

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, today announced financial results for the third quarter ended September 30, 2024, and provided a business update. “With the clearance of our first clinical trial application (CTA) for our lead program, PBGENE-HBV, we have arrived at the next phase of Precision's jou.

Precision BioSciences (DTIL) Surges 6.1%: Is This an Indication of Further Gains?
zacks.com01 November 2024 Sentiment: POSITIVE

Precision BioSciences (DTIL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Precision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data and Phase 1 Clinical Trial Plans on November 15, 2024
businesswire.com28 October 2024 Sentiment: POSITIVE

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, today announced it will host a Hepatitis B Investor Event on Friday, November 15, 2024, from 7:00 a.m. – 8:30 a.m. PST prior to the American Association for the Study of Liver Diseases (AASLD) Meeting. The event will feature Key Opinion Leaders in the field of Hepat.

Precision BioSciences to Participate in Upcoming Longwood Boston CEO and Guggenheim Healthcare Conferences
businesswire.com21 October 2024 Sentiment: POSITIVE

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, today announced that it will participate in the following upcoming investor conferences. Longwood Boston CEO Conference Date: Monday, October 28, 2024 Time: 11:10 AM ET Title: Expanding Platform Potential Format: Panel Guggenheim Inaugural Healthcare Conference Date.

Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Congress
businesswire.com16 October 2024 Sentiment: POSITIVE

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL) is an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion which is necessary for diseases where a defective gene is remedied by expression of a new DNA sequence, today announced a poster presentation at the upcoming European Society of Gene & Cell Therapy (ESGCT) Congress being held October 22-25,.

Precision BioSciences to Present at the Upcoming H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
businesswire.com03 October 2024 Sentiment: POSITIVE

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits including viral gene elimination, today announced that the Company will present during a fireside chat at the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference taking place October 8, 2024. Presentation Details: Date: October 8, 2024 Time: 11:00AM ET Format: F.

Wall Street Analysts Think Precision BioSciences (DTIL) Could Surge 277.6%: Read This Before Placing a Bet
zacks.com13 September 2024 Sentiment: POSITIVE

The average of price targets set by Wall Street analysts indicates a potential upside of 277.6% in Precision BioSciences (DTIL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Despite Fast-paced Momentum, Precision BioSciences (DTIL) Is Still a Bargain Stock
zacks.com11 September 2024 Sentiment: POSITIVE

Precision BioSciences (DTIL) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

  • 1(current)

What type of business is Precision BioSciences?

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

What sector is Precision BioSciences in?

Precision BioSciences is in the Healthcare sector

What industry is Precision BioSciences in?

Precision BioSciences is in the Biotechnology industry

What country is Precision BioSciences from?

Precision BioSciences is headquartered in United States

When did Precision BioSciences go public?

Precision BioSciences initial public offering (IPO) was on 28 March 2019

What is Precision BioSciences website?

https://www.precisionbiosciences.com

Is Precision BioSciences in the S&P 500?

No, Precision BioSciences is not included in the S&P 500 index

Is Precision BioSciences in the NASDAQ 100?

No, Precision BioSciences is not included in the NASDAQ 100 index

Is Precision BioSciences in the Dow Jones?

No, Precision BioSciences is not included in the Dow Jones index

When was Precision BioSciences the previous earnings report?

No data

When does Precision BioSciences earnings report?

The next expected earnings date for Precision BioSciences is 27 March 2025